

Application No. 09/897,042  
Amendment dated May 11, 2004  
Reply to Office Action of February 11, 2004

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

Claims 1-24 (Cancelled).

Claim 25 (Previously Presented): The immunogen according to claim 28, wherein the fragment comprises SEQ ID NO:19.

Claim 26 (Previously Presented): The immunogen according to claim 28, wherein the fragment comprises SEQ ID NO:20.

Claim 27 (Previously Presented): The immunogen according to claim 28, wherein the fragment comprises SEQ ID NO:21.

Claim 28 (Previously Presented): An immunogen derived from Bet v 1 protein allergen, comprising

- a) a non-anaphylactic immunogenic recombinant fragment of the protein allergen, said fragment comprising an IgG epitope and an IgE epitope of the protein allergen partly but not completely overlapping;
- b) a polymeric form of said fragment, in which form the fragment constitutes the monomeric units, wherein said monomeric units are separated from each other by an oligopeptide linker; or

Application No. 09/897,042  
Amendment dated May 11, 2004  
Reply to Office Action of February 11, 2004

c) a non-anaphylactic recombinant polymeric form of said protein allergen having 2 to 10 monomeric units in which the protein allergen constitutes the monomeric units, wherein said monomeric units are separated from each other by an oligopeptide linker.

Claim 29 (Previously Presented): The immunogen according to claim 28, wherein the polymeric form of said fragment is recombinantly produced.

Claim 30 (Previously Presented): The immunogen of claim 28, wherein said immunogen is according to (b) or (c) and said oligopeptide linker comprises 1-30 amino acid residues.

Claim 31 (Previously Presented): The immunogen of claim 30, wherein said amino acid residues are hydrophilic.